

Dishman Pharma expands plant capacity

City-based Dishman Pharmaceuticals and Chemicals Ltd (DPCL) has commissioned three active pharmaceutical ingredient (API) facilities at Bavla.

City-based Dishman Pharmaceuticals and Chemicals Ltd (DPCL) has commissioned three active pharmaceutical ingredient (API) facilities at Bavla.

The three API facilities that provide additional capacity for undertaking contract manufacturing have been set up at a cost of Rs.1.5 billion (\$37.5 million), the company said Wednesday in a filing with the Bombay Stock Exchange (BSE).

Another API facility which will be dedicated for cytotoxic and cytotoxic compounds such as anti-cancer drugs is in the process of installation and is expected to be commissioned by the end of 2008, the company said. The capital expenditure of the fourth API ranges from Rs.250 million to Rs.300 million.

With the launch of new facilities, the company's revenue would go up significantly in the coming years, DPCL chief financial officer V.V.S Murthy told IANS.

According to company officials, the pharmaceutical industry is becoming increasingly competitive in the post-intellectual property rights era. The intense competition has provided good opportunities for DPCL to become an outsourcing partner to drug multi-nationals.

The company has already acquired a large area of land in Bavla. 14 km from Ahmedabad, to develop 'state-of-the-art' production and research facilities, sources said.

- Indo Asian News Service